IS7219A - Lyfjablanda sem inniheldur (R) -bíkalútamíð - Google Patents

Lyfjablanda sem inniheldur (R) -bíkalútamíð

Info

Publication number
IS7219A
IS7219A IS7219A IS7219A IS7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A IS 7219 A IS7219 A IS 7219A
Authority
IS
Iceland
Prior art keywords
bicalutamide
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Application number
IS7219A
Other languages
English (en)
Inventor
Kay Cahill Julie
Frances Bateman Nicola
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of IS7219A publication Critical patent/IS7219A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7219A 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð IS7219A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation
PCT/GB2002/004621 WO2003032950A1 (en) 2001-10-15 2002-10-11 Pharmaceutical formulation comprising (r) -bicalutamide

Publications (1)

Publication Number Publication Date
IS7219A true IS7219A (is) 2004-04-14

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7219A IS7219A (is) 2001-10-15 2004-04-14 Lyfjablanda sem inniheldur (R) -bíkalútamíð

Country Status (19)

Country Link
US (1) US20060058381A1 (is)
EP (1) EP1439823A1 (is)
JP (1) JP3639587B2 (is)
KR (1) KR20050035163A (is)
CN (1) CN1571658A (is)
AR (1) AR036877A1 (is)
BR (1) BR0213248A (is)
CA (1) CA2462219A1 (is)
CO (1) CO5580755A2 (is)
HU (1) HUP0401369A3 (is)
IL (1) IL161306A0 (is)
IS (1) IS7219A (is)
MX (1) MXPA04003520A (is)
NO (1) NO20041485L (is)
PL (1) PL368226A1 (is)
RU (1) RU2004115023A (is)
SE (1) SE0103424D0 (is)
WO (1) WO2003032950A1 (is)
ZA (1) ZA200402729B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60206889T2 (de) * 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
BRPI0507007A (pt) 2004-01-20 2007-06-05 Novartis Ag formulação e processo de compressão direta
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森***医疗有限责任公司 恩杂鲁胺制剂
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
DK0580860T4 (da) * 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
DE60206889T2 (de) * 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
IL157955A0 (en) * 2001-04-02 2004-03-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Also Published As

Publication number Publication date
CN1571658A (zh) 2005-01-26
BR0213248A (pt) 2004-09-28
AR036877A1 (es) 2004-10-13
PL368226A1 (en) 2005-03-21
US20060058381A1 (en) 2006-03-16
NO20041485L (no) 2004-04-13
JP2004521963A (ja) 2004-07-22
EP1439823A1 (en) 2004-07-28
ZA200402729B (en) 2005-01-13
MXPA04003520A (es) 2004-07-23
KR20050035163A (ko) 2005-04-15
HUP0401369A2 (hu) 2004-11-29
JP3639587B2 (ja) 2005-04-20
RU2004115023A (ru) 2005-04-10
IL161306A0 (en) 2004-09-27
HUP0401369A3 (en) 2006-05-29
CO5580755A2 (es) 2005-11-30
CA2462219A1 (en) 2003-04-24
SE0103424D0 (sv) 2001-10-15
WO2003032950A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
IS2893B (is) Lyfjasamsetning sem inniheldur lantanefnasambönd
FI20011478A (fi) Farmaseuttinen koostumus
GB0111597D0 (en) Pharmaceutical compositions
AU2003276549A8 (en) Pharmaceutical compositions containing a biguanide-glitazone combination
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
EE200300589A (et) Ravimkoostised
EP1408896A4 (en) PHARMACEUTICAL COMPOSITION
GB0101227D0 (en) Pharmaceutical compounds
GB0101225D0 (en) Pharmaceutical compounds
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
GB0129117D0 (en) Pharmaceutical composition
GB0116107D0 (en) Pharmaceutical composition
GB0127805D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
PL370037A1 (en) Pharmaceutical composition
IS6857A (is) Lyfjafræðileg samsetning sem innheldur sítalópram
GB2382302B (en) Pharmaceutical compositions
EE200300378A (et) Farmatseutiline kompositsioon
AU2002342940A8 (en) New pharmaceutical compounds
HU0103049D0 (en) Pharmaceutical composition
GB0125061D0 (en) Pharmaceutical composition
GB0126732D0 (en) Pharmaceutical compositions